Taking a treatment from the laboratory in to clinical trials and then to becoming available for use is a complex and expensive process. We talk with Dr Kiran Reddy, President and CEO of Praxis Precision Medicines, about the plans for the RC-222 treatment program with the eventual goal of having a treatment available for SCN2A gain-of-function epilepsies. Hosted by Kris Pierce and David Cunnington, parents of Will, who has SCN2A. Leave a review and subscribe via Apple Podcasts.  You can also find SCN2A Insights on Spotify, and Google Podcasts or in your podcast app Links:  Praxis Precision Medicines Antisense oligonucleotide therapy for gain-of-function SCN2A epilepsies Natural History Study – podcast on SCN2A natural history study See omnystudio.com/listener for privacy information.

Ver todos los episodios